First Wave BioPharma can’t seem to catch a break in its efforts to bring a new drug to market for pancreatic insufficiency problems that affect most patients with cystic f
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh